Clinical Trial Update: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CNTO 2476 for visual acuity impairment due to geographic atrophy from age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• CNTO 2476

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Visual Acuity, Geographic Atrophy | Phase 2 | Status: WITHDRAWN